AUCATZYL Launch and Growth - AUCATZYL achieved net product sales of $9 million in Q1 2025[8] - Approximately 90% of total U S medical lives are covered for AUCATZYL[10] - 39 Treatment Centers Authorized as of 05/07/25[8] - Conditional marketing authorization in the UK received April 25, 2025, with EMA decision expected in H2 2025[12] Obe-cel Development and Potential - Obe-cel demonstrated a high MRD-negative complete remission rate of 94% in r/r adult and pediatric acute B cell lymphoblastic leukemia (ALL) patients[17] - In non-Hodgkin lymphoma, obe-cel showed a high metabolic complete remission rate of 88% in r/r LBCL and 95% in r/r FL[17] - Preliminary CARSLYLE SLE P1 trial data shows 10+ point drop in SLEDAI-2K scores and 3 of 6 patients with renal CRs by month 3[22] Financial Status - The company's cash, cash equivalents, and marketable securities totaled $516 6 million as of Q1 2025[41] - Net product revenue for Q1 2025 was $8 982 million[40] Upcoming Milestones - The company anticipates dosing the first patient in the Phase 2 trial for lupus nephritis by year-end 2025[32] - The company anticipates dosing the first patient in the progressive MS Phase 1 trial by year-end 2025[37]